Cell Line Development Market Research Report: Information By Type (Primary cell, Hybridoma Cell Line, Continuous Cell Line, Recombinant Cell Line), By Product (Equipment, Media and Reagents), Scource Mammalian cells, Non Mammalian cells), Application (Drug Discovery, Bioproduction, Tissue Engineering, Others), Region (North America, Europe, Asia-Pacific, Rest of the World) Forecast till 2027Market HighlightsAccording to MRFR analysis, the global cell line development market is expected to register a CAGR of 12.5 from 2021 to 2027 and hold a value of USD 10,700 million by 2027.The global cell line development market is driven by the increasing R in the pharmaceutical and biopharmaceutical industry, focusing on cell line development.
The developing economiesare also contributing to the increasing R activities.
For instance,in October 2019, ATCC launched a new authentication service that helps researchers easily confirm mouse cell lines’ identity.
The service demonstrates ATCC’s continued leadership in developing global biological standards.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/9131 Regional AnalysisBased on region, North America is anticipated to dominate the global cell line development market in the year 20120, owing to the factors such as the growing number of application of cell line development in new treatment pathway for various diseases such as cancer and other neurological disease, well-established healthcare infrastructure, government support to accelerate research in biotechnology and biopharmaceutical industry, and presence of key players in this region involved in product launch, expansion, acquisition & strategic collaborations.
The recombinant cell line consists of recombinant DNA.
The advances in rDNA technology offers enzymes, synthetic hormones immunobiological and anti-cancer agents that is contributing to the market growth of this segment.